Hwang, In Gyu and Kwon, Minsuk and Kim, Jin Won and Kim, Se Hyun and Lee, Yun-Gyoo and Kim, Jin Young and Koh, Su-Jin and Ko, Yoon Ho and Shin, Seong Hoon and Hong, Soojung and Kim, Tae-Yong and Kim, Sun Young and Kim, Hyun Jung and Kim, Hyo Jung and Lee, Myung Ah and Kwon, Jung Hye and Hong, Yong Sang and Lee, Kyung Hee and Bae, Sung Hwa and Koo, Dong-Hoe and Kim, Jee Hyun and Woo, In Sook (2021) Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. Cancers, 13 (2). p. 331. ISSN 2072-6694
cancers-13-00331.pdf - Published Version
Download (917kB)
Abstract
Old age alone does not reflect an intolerability to chemotherapy. However, upfront dose reduction (UDR) of the first cycle of first-line palliative chemotherapy has sometimes been chosen by physicians for older adults with metastatic cancer due to concerns regarding adverse events. The development of predictive factors for UDR of palliative chemotherapy would be helpful for treatment planning among older adults. This was a secondary analysis of a study on predicting adverse events of first-line palliative chemotherapy in 296 patients (≥70 years) with solid cancer. We assessed the prevalence of UDR of the first cycle of first-line chemotherapy and the association of UDR with the variables of geriatric assessment (GA) and chemotherapy compliance. Among the 296 patients, 177 (59.8%) patients were treated with UDR. The mean percentage of UDR for the total patient group was 19.2% (range: 4–47%) of the standard dose. In a multivariate analysis, poor performance status (PS) and living without a spouse were independent predictive factors of UDR of first-line palliative chemotherapy in older adults. Patients with UDR showed fewer grade 3–5 adverse events versus the standard dose group. Study completion as planned was significantly higher in the UDR group versus the standard dose group. Older adults with UDR better tolerated chemotherapy than patients with a standard dose.
Item Type: | Article |
---|---|
Subjects: | Journal Eprints > Medical Science |
Depositing User: | Managing Editor |
Date Deposited: | 22 Feb 2023 06:07 |
Last Modified: | 17 Jun 2024 06:02 |
URI: | http://repository.journal4submission.com/id/eprint/520 |